GOLDMAN SACHS: These 20 beaten-down stocks are perfectly primed for a huge comeback — and you should buy them for cheap right now

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 39 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 19%
  • Publisher: 51%

Business News News

Business Business Latest News,Business Business Headlines

These value stocks are already on the rise but still trading at a steep discount to Goldman Sachs' price forecasts.

Investors who bought companies thought to be undervalued have benefitted from the recent outperformance of value stocks over the fastest earnings growers. The past few weeks have allowed value investors to take a rare victory lap, considering how much growth stocks have outperformed throughout this bull market.biggest beneficiariesDerivatives strategists at Goldman Sachs have compiled a list of 20 stocks that"have the potential for continued asymmetric upside.

Investors have already discounted these companies heavily. The average stock on this list has underperformed the"While fundamentals will also determine the long-term trajectory of stocks, we use signals from options and credit markets to identify 20 value stocks from among those where our analysts' estimates show strong value scores," Goldman's Vishal Vivek said in a recent note to clients.

The stocks are all buy- or neutral-rated and were skimmed from the top quintile of Goldman's valuation portfolio. Their credit default swap spreads are all tighter than 200 basis points and have not risen over the past month. They are listed below, sorted from stocks with the smallest drawdown over the past year to those with the largest.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 729. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

The batch of companies IPOing in 2019 is the least profitable since the tech bubble, Goldman Sachs findsNone of this year's newly tradable biotech companies are expected to turn a profit for the next three years, Goldman found.
Source: BusinessInsider - 🏆 729. / 51 Read more »